Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa.
Cruz-Flores
Salvador
S
D000925:Anticoagulants / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000188:drug therapy*; D005167:Factor VII / Q000009:adverse effects* / Q000627:therapeutic use; D005169:Factor VIII / Q000627:therapeutic use; D015942:Factor VIIa; D005340:Fibrinogen / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology*; D010949:Plasma; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012107:Research Design; D012189:Retrospective Studies; D012306:Risk; D015983:Selection Bias; D014336:Troponin / Q000097:blood; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D011994:Recombinant Proteins; D014336:Troponin; C026912:cryoprecipitate coagulum; D014859:Warfarin; D005167:Factor VII; D005169:Factor VIII; D005340:Fibrinogen; C103587:recombinant FVIIa; D015942:Factor VIIa